Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "India-CRO"

3 News Found

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth
News | February 10, 2026

GSK India crosses Rs. 1,000 crore mark, key portfolios drive 8.1% topline growth

Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum

India crosses ‘200 Crore’ COVID-19 vaccinations
News | July 18, 2022

India crosses ‘200 Crore’ COVID-19 vaccinations

PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive

Parexel acquires Vitrana to strengthen AI-driven patient safety capabilities
Clinical Trials | April 30, 2026

Parexel acquires Vitrana to strengthen AI-driven patient safety capabilities

Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations

Latest Stories

BD, Suttons Creek partner to streamline combination product development

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

GSK wins regulatory boost for once-monthly liver drug efimosfermin in MASH push

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India
Our hybrid model combines global manufacturing with local clinical scale: Kavinder Beniwal, Chief Operational Officer, Motorica India
Kavinder Beniwal Chief Operational Officer, Motorica India
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.

Packaging